BlossomHill Therapeutics, Inc. Common Stock (BLSM) stock: key figures, P/E, revenue and dividend

Health Care · United States

Price
14.24 USD
Market cap
414.12 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
45.97 %
Return on assets (ROA)
-37.16 %

BlossomHill Therapeutics, Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Operating income-36.40 m USD-64.02 m USD
EBIT-36.40 m USD-64.02 m USD
Net income-30.70 m USD-60.56 m USD
Diluted EPS – continuing operations-1.06 USD-2.08 USD

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.